Jianfeng Group announced that recently, its wholly-owned subsidiary Jianfeng Pharmaceutical received the “Drug Registration Certificate” for injectable tedizolamide phosphate approved and issued by the State Drug Administration. The specification is 200mg, and the approval number is valid until July 20, 2031. As of the announcement date, the drug project invested about 125.192 million yuan in research and development. Currently, 22 companies have been approved to register and market this drug. This certification indicates that Jianfeng Pharmaceutical has production and sales qualifications, which is beneficial to a rich product line, but production and sales are affected by many factors, and there is uncertainty.

Jianfeng Group announced that recently, its wholly-owned subsidiary Jianfeng Pharmaceutical received the “Drug Registration Certificate” for injectable tedizolamide phosphate approved and issued by the State Drug Administration. The specification is 200mg, and the approval number is valid until July 20, 2031. As of the announcement date, the drug project invested about 125.192 million yuan in research and development. Currently, 22 companies have been approved to register and market this drug. This certification indicates that Jianfeng Pharmaceutical has production and sales qualifications, which is beneficial to a rich product line, but production and sales are affected by many factors, and there is uncertainty.